Scholarlink

<p>With the rapid progress in artificial intelligence (AI) and digital pathology, prognosis prediction for non-small cell lung cancer (NSCLC) patients has become a critical component of personalized medicine. In this study, we developed a multimodal AI model that integrated whole-slide images and dense clinical data to predict disease-free survival (DFS) and overall survival (OS) with high accuracy for NSCLC patients undergoing surgery. Utilizing data from 618 patients at Beijing Chest Hospital, the model achieved areas under the curve (AUC) of 0.8084 for predicting progression and 0.8021 for predicting death in the test set. Importantly, the model attained balanced accuracies of 0.7047 for predicting progression and 0.6884 for predicting death. By categorizing patients into high-risk and low-risk groups, the model identified significant differences in survival outcomes, with hazard ratios of 4.85 for progression and 4.57 for death, both with <i>p</i> values below 0.0001. Additionally, it uncovered novel digital biomarkers associated with poor prognosis, offering further insights into NSCLC treatment. This model has the potential to revolutionize postoperative decision-making by providing clinicians with a precise tool for predicting DFS and OS, thereby improving patient outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Accurate prediction of disease-free and overall survival in non-small cell lung cancer using patient-level multimodal weakly supervised learning

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月19日

查看全文
  • Yongmeng Li,
  • Xiaodong Chai,
  • Moxuan Yang,
  • Jiahang Xiong,
  • Junyang Zeng,
  • Yun Chen,
  • Gang Xu,
  • Haifeng Lin,
  • Wei Wang,
  • Shuhao Wang,
  • Nanying Che

摘要

With the rapid progress in artificial intelligence (AI) and digital pathology, prognosis prediction for non-small cell lung cancer (NSCLC) patients has become a critical component of personalized medicine. In this study, we developed a multimodal AI model that integrated whole-slide images and dense clinical data to predict disease-free survival (DFS) and overall survival (OS) with high accuracy for NSCLC patients undergoing surgery. Utilizing data from 618 patients at Beijing Chest Hospital, the model achieved areas under the curve (AUC) of 0.8084 for predicting progression and 0.8021 for predicting death in the test set. Importantly, the model attained balanced accuracies of 0.7047 for predicting progression and 0.6884 for predicting death. By categorizing patients into high-risk and low-risk groups, the model identified significant differences in survival outcomes, with hazard ratios of 4.85 for progression and 4.57 for death, both with p values below 0.0001. Additionally, it uncovered novel digital biomarkers associated with poor prognosis, offering further insights into NSCLC treatment. This model has the potential to revolutionize postoperative decision-making by providing clinicians with a precise tool for predicting DFS and OS, thereby improving patient outcomes.